- acute myeloid leukemia (AML)
- aplastic anemia
- myelodysplastic syndromes (MDS)
- myeloproliferative neoplasms (MPN)
Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based novel therapies for patients with MPNs and AML. Dr. Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML. Additionally, he holds multiple administrative roles at Mount Sinai including Chair of the Leukemia Disease Management Team, Co-Chair of the Hematologic Malignancy Disease Focus Group, and full member of the Tisch Cancer Institute Protocol and Review Monitoring Committee.
- accepting new patients